AUS
NZ
UK
CA
USA
IND
Highlights
hVIVO plc presented data from multiple novel human challenge models at leading global vaccine conferences.
New hMPV, RSV B, and Omicron models demonstrated strong safety and tolerability profiles.
The company strengthened its global leadership in human challenge clinical research through advanced vaccine efficacy platforms.
hVIVO plc, listed on the FTSE AIM 100 Index, announced positive data from its new hMPV, RSV B, and Omicron human challenge models at major European conferences, strengthening its position in clinical research innovation.
hVIVO plc operates within the Healthcare Stocks sector and is listed on the FTSE AIM 100 Index. The company (LSE:HVO) has released new findings from presentations at two major international vaccine and influenza conferences. These scientific presentations mark a key development in the clinical research field, showcasing hVIVO’s expanding expertise in early-phase medical trials and infectious disease modelling. For further context and updates on ftse today live.
Breakthrough Data from Human Challenge Models
hVIVO plc disclosed data from multiple novel human challenge models, each exhibiting acceptable safety and tolerability standards. These results were unveiled at the European Scientific Working Group on Influenza (ESWI) Conference in Valencia and the World Vaccine Congress Europe in Amsterdam. The data highlighted the company’s continuous development of innovative challenge agents designed to improve the precision and speed of vaccine and antiviral research.
The human challenge trials presented by hVIVO demonstrated advanced scientific methodologies aimed at accelerating the development of vaccines against key respiratory pathogens. Each model was engineered to maintain high infection and symptomatic response rates while ensuring controlled clinical conditions suitable for global vaccine research studies.
Innovation in hMPV Challenge Model Development
At the ESWI Conference, hVIVO’s team presented data from its contemporary Human Metapneumovirus (hMPV) challenge model. The study incorporated a recently developed strain representing a critical step in the evolution of respiratory virus research. The model performed effectively under clinical testing conditions, showing favourable comparability with the company’s established RSV A model.
This hMPV challenge model achieved measurable infection outcomes and immune response consistency through controlled virology assessment using molecular techniques. The development establishes a new global benchmark for the study of hMPV and provides a foundational platform for evaluating vaccines and therapeutics targeting the Metapneumovirus family.
SARS-CoV-2 Omicron Challenge Model Performance
The company’s presentation titled “Development of a SARS-CoV-2 Omicron BA5 human challenge model” provided insights into the first commercially available Omicron challenge model. Conducted in participants with prior vaccination and existing antibodies, this study validated the suitability of the Omicron BA5 model for controlled use in vaccine and treatment studies.
Key insights focused on optimising timing within dosing protocols post-inoculation. This approach was essential to achieving consistent infection dynamics while maintaining safety standards. The model demonstrated effective replication and measurable response patterns, representing a refined method for studying the Omicron variant in human challenge environments.
Enhanced RSV B Challenge Model and Combination Vaccine Testing Platform
At the World Vaccine Congress Europe, hVIVO’s Chief Scientific Officer presented data related to the world’s first Respiratory Syncytial Virus B (RSV B) challenge model. This innovation forms a vital component of hVIVO’s integrated vaccine efficacy testing platform, which combines studies of RSV, hMPV, and Parainfluenza Virus (PIV).
The RSV B challenge model achieved strong infection rates within a controlled and ethically monitored framework. The collected data supported the company’s capability to evaluate multi-pathogen vaccine efficacy. Additionally, the ongoing collection of PIV samples enables comprehensive assessment of next-generation combination vaccines. Through this integrated platform, hVIVO can assess the performance of each vaccine component, thereby advancing broader vaccine development frameworks for respiratory infections.
Scientific Recognition and Expanded Clinical Capabilities
hVIVO’s participation in global scientific forums such as ESWI and the World Vaccine Congress underscores its established leadership in the clinical research ecosystem. These conferences provided platforms for detailed scientific discourse among global experts in immunology and virology.
Dr Andrew Catchpole, Chief Scientific Officer at hVIVO, highlighted the data’s contribution to reinforcing the company’s role in developing human challenge models across diverse respiratory pathogens. The consistency and robustness of the results further validate the technical capacity of hVIVO’s clinical and laboratory teams. The findings also reaffirm the company’s commitment to addressing evolving global health challenges through scientifically rigorous and ethically sound research frameworks.
The organisation continues to expand its research infrastructure across multiple European locations, including London, Mannheim, and Kiel. Its facilities offer comprehensive clinical development services, spanning from early-phase studies to later-stage clinical research. The London site remains the largest dedicated quarantine facility of its kind globally, serving as the cornerstone for conducting complex infectious disease trials.
Expanding Global Research Services
Through its subsidiaries, hVIVO plc provides integrated scientific and operational support for pharmaceutical and biotechnology organisations worldwide. Its German subsidiary, CRS, operates clinical facilities equipped for early-phase and proof-of-concept studies. Another subsidiary, Venn Life Sciences, delivers biometry and early drug development consulting services, complementing hVIVO’s clinical capabilities.
These operations collectively establish hVIVO as a leading entity in early-stage drug development and challenge trial design. The company’s holistic approach enables seamless progression from preclinical development through to Phase II studies, supported by efficient patient recruitment and advanced laboratory analysis.
The company’s commitment to scientific advancement continues to strengthen its global reputation within the healthcare research field. Its focus remains on supporting international efforts to improve vaccine design, therapeutic validation, and translational research methodologies.
